How to Prepare Clinical Evaluation Documentation for Overseas Registration of Rehabilitation Equipment?

Published: 2026-08-16 12:34 | Updated: 2026-08-16 12:34

Key Summary

The core of preparing clinical evaluation data for overseas registration of rehabilitation equipment is to first determine whether the target country regulates the product as a medical device, its risk classification, and registration pathway, then assess whether existing NMPA, CE, FDA, ISO 13485, or MDSAP documentation can be reused. Enterprises need to prepare product technical files, risk management reports, performance verification and biocompatibility data, and determine the clinical evaluation pathway based on product classification and intended use. Most rehabilitation devices can be exempted from clinical trials through equivalence argumentation and literature data, but high-risk neuromuscular stimulators or implantable rehabilitation devices may still require locally recognized clinical trials. Common risks include insufficient equivalence argumentation, omission of key databases in literature searches, failure to cover special requirements of the target country, incomplete localization of labels and instructions, and lack of a local agent and post-market maintenance plan. It is recommended that enterprises confirm the target country's regulatory framework and clinical evidence acceptance standards early in the project, appoint a local agent in advance, and establish a complete evidence chain including clinical evaluation reports, full-text literature, performance data, and post-market surveillance records to avoid registration deficiencies and delays.

Compiled from AIMEILI's registration practice question bank, medical device international registration knowledge base, and public regulatory information; specific projects should be based on the latest requirements of the target country's regulatory authority and the product's data foundation.

Applicable Scenarios and Core Issues

Rehabilitation equipment is a broad category, including wheelchairs, walkers, rehabilitation training devices, cervical traction devices, physical therapy instruments, neuromuscular stimulators, cognitive rehabilitation software, and more. The risk levels of different products vary greatly, and the clinical evaluation requirements for overseas registration are completely different. Enterprises must first clarify which category their product belongs to and the regulatory boundaries of the target country.

The core question is not 'whether to conduct clinical trials' but 'what evidence is used to demonstrate the safety and effectiveness of the product.' For most passive rehabilitation devices and low-to-medium risk physical therapy equipment, a clinical evaluation report can be used, supported by equivalence argumentation and literature data; however, for active implantable, neurostimulation, or products claiming therapeutic functions, the target country is likely to require targeted clinical data.

Registration Determination Logic

First, determine whether the product is within the scope of medical device regulation in the target country. For example, the US FDA may classify it as Class I or II, under the EU MDR it may be Class I or IIa, and GHWP member countries such as Saudi Arabia, Indonesia, and Brazil also have their own classification catalogs. Classification determines the registration pathway, technical documentation requirements, and whether clinical evaluation is exempted.

Second, determine the risk classification, registration pathway, and applicant entity. The US typically requires 510(k) or PMA, the EU requires Notified Body involvement, and many Southeast Asian countries require submission through a local agent. Enterprises need to confirm whether existing CE or FDA technical files can be used or whether they need to be reorganized according to target country requirements.

Third, assess whether existing NMPA, CE, FDA, ISO 13485, MDSAP, or other market documentation can be directly reused. Generally, technical files, risk management reports, and performance verification reports can be reused, but clinical evaluation reports often need to be rewritten according to target country regulations, especially the equivalence argumentation which must cite standards and clinical data recognized by the target country.

Documentation and Evidence

Clinical evaluation documentation for overseas registration of rehabilitation equipment should include product technical files, risk management reports, performance verification data, biocompatibility data (if applicable), clinical evaluation reports, literature search reports, equivalence comparison tables, labels and instructions, and post-market surveillance plans. The clinical evaluation report should clearly state the evaluation objective, basis for selecting equivalent products, literature databases, search strategies, inclusion/exclusion criteria, data analysis, and conclusions.

For products using equivalence argumentation, the equivalent product must be sufficiently similar in intended use, technical characteristics, and biological characteristics, and must provide legal marketing evidence and sufficient clinical data. Literature searches should cover mainstream databases such as Medline, Embase, and Cochrane, and complete search strategies and screening records should be retained to respond to regulatory deficiencies.

Label and instruction manual localization is also part of the clinical evaluation materials, because indications, target population, contraindications, and methods of use directly affect the claimed scope of safety and effectiveness. Local agents and authorized representatives must participate in document confirmation to ensure clarity of certificate holder and post-market obligations.

Common Errors

The most common problem for enterprises is treating a registration project as a simple document submission, without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Directly translating domestic NMPA documents and submitting them without rearranging evidence according to the target market pathway.
• Having too many model specifications but insufficient testing reports, clinical evidence, or label coverage.
• Selecting local agents only based on sales cooperation, without clearly defining regulatory responsibilities, certificate control rights, and post-market maintenance responsibilities.
• Inconsistencies among labels, instructions, promotional materials, and registration documents, leading to deficiencies or post-market compliance risks.
• Failing to plan for multi-country document reuse in advance, resulting in duplicate work, increased costs, and extended timelines.

Enterprise Preparation Checklist

• Confirm the target country and regulatory classification, and determine whether the product is a medical device.
• Review existing technical files and clinical data, and identify reusable and locally required content.
• Prepare complete product technical files and technical parameters, including software descriptions and algorithm explanations.
• Develop a risk management report, identifying clinically relevant hazards and risk control measures.
• Write a clinical evaluation plan and select the evaluation pathway: equivalence argumentation, literature evaluation, or clinical trial.
• Perform a systematic literature search, retaining search strategies and screening process records.
• Complete an equivalence comparison table, collecting evidence of the equivalent product's indications, technical characteristics, and clinical data.
• Confirm the local agent or authorized representative, and sign an agreement that includes change and renewal responsibilities.

AIMEILI Perspective

The most common misconception is believing that obtaining CE or FDA approval means other countries will automatically recognize the product. In reality, each country has its own classification and clinical data acceptance standards. GHWP member states in particular have varying requirements for equivalence argumentation and local literature. In the early stages of a project, enterprises should spend a small amount on regulatory research to confirm the acceptable clinical evaluation pathway, rather than directly investing in clinical trial costs.

Technical files, risk management reports, and performance verification reports can be reused, but the literature search and equivalence argumentation in the clinical evaluation report must be localized. A local agent is not just a document submission channel; they are responsible for communicating with regulatory authorities, receiving deficiency responses, maintaining certificates, and even determining the product's continued market presence. Enterprises must maintain control of certificates to ensure smooth execution of future changes and renewals.

The best way for multi-country registration is to use one set of technical files as a base and build clinical evaluation modules split by country. This reduces duplicate work and allows quick identification of the same risk points in other countries when a deficiency is issued in one country, enabling early modifications to avoid batch deficiencies.

Common Follow-up Questions

When can rehabilitation equipment be exempted from clinical trials?

Most low- and medium-risk rehabilitation equipment can be exempted from clinical trials through equivalence argumentation and literature evaluation, provided that it is equivalent to a legally marketed product in terms of intended use, technical characteristics, and biological characteristics, and that there are no risks requiring clinical data to eliminate. However, exemption does not mean no clinical evaluation; enterprises still need to produce a formal clinical evaluation report.

Which databases should literature searches cover?

It is recommended to cover Medline/PubMed, Embase, Cochrane Library, Scopus, as well as local literature indexes of the target country. Search strategies should include combinations of product name, intervention method, disease area, and alternative therapies. Preserve search dates, keywords, and hit results to provide a complete traceable record during deficiency responses.

Does clinical evaluation documentation need to be translated into the local language?

Most countries require the summary or full text of the clinical evaluation report to be translated into the local language, such as Portuguese in Brazil, Indonesian in Indonesia, and Arabic in Middle Eastern countries. It is recommended to prepare an English draft and then localize the translation according to target country requirements, with local agents reviewing terminology and indication consistency. Translation errors may expand or narrow the scope of indications, directly affecting approval.

Quality System and Evidence Consistency

From the perspective of regulatory review, quality system documentation is not an isolated certificate. Regulatory authorities typically focus on consistency among the manufacturer name, production address, product scope, certificate validity, applicable standards, and technical files. If the ISO 13485 certificate scope does not match the declared product, or if the production address, model/specification, or instruction manual version is inconsistent with testing reports, even a well-prepared document package may be subject to supplemental requests.

Enterprises should establish an evidence consistency checklist before submission, mapping product names, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management versions, label/instruction versions, and quality system certificates. This seemingly basic action can significantly reduce the probability of deficiencies, especially for applications involving multiple GHWP member states or multiple product lines.

Localization and Agent Responsibilities

Target market registration projects usually involve arrangements for local agents, authorized representatives, importers, or registration holders. Enterprises need to confirm in advance whether the local partner is only responsible for submitting documents or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and long-term market stability.

Labels, instructions, and authorization documents cannot be simply translated. Enterprises should verify local language requirements, product claim boundaries, warning statements, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For enterprises that already have CE, FDA, NMPA, or other market documents, the focus of localization is to convert reusable evidence into a submission structure acceptable to the target country, rather than writing a completely new set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Enterprises must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many enterprises invest significant effort in obtaining registration but neglect post-market maintenance. When production address changes, model extensions, instruction manual updates, or agent changes occur, certificates may become disconnected from market sales.

AIMEILI recommends including this issue in the annual international registration plan: first clarify target market priorities, then establish a reusable document package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only improving registration efficiency in a single country, but more importantly enabling enterprises to develop replicable overseas compliance capabilities, reducing the cost of starting from scratch each time they enter a new market.

Continued Reading

• How to Prepare Clinical Evaluation Documentation for Imaging Equipment Overseas Registration?
• How to Prepare Clinical Evaluation Documentation for Patient Monitoring Equipment Overseas Registration?
• How to Prepare Clinical Evaluation Documentation for Sterile Consumables Overseas Registration?
• How to Prepare Clinical Evaluation Documentation for AI Medical Devices Overseas Registration?
• How to Prepare Clinical Evaluation Documentation for Home Medical Devices Overseas Registration?
• How to Divide Authorized Representative Responsibilities for Imaging Equipment Overseas Registration?

Content Review and Applicability Boundary

Content Author: AIMEILI Regulatory Editorial Department; Professional Review: AIMEILI Medical Device International Registration Project Team; Source Principle: Official regulatory authorities, international organizations, standards organizations, and public regulatory information are prioritized; industry media and project experience are used only as supplementary reference. Applicability Boundary: This article is for preliminary understanding, documentation preparation, and project planning, and does not replace formal requirements, testing conclusions, or legal advice from the target country's regulatory authority.